ArticleNature2023
STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 1 pooled it
35.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 1 synthesis or guideline pooled it, 209 citations in OpenAlex.
- Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Nanoadjuvant-based membrane poration boosts antitumor immunity via modulating mitochondrial metabolism to downregulate PD-L1 and upregulate STING.Bioactive materials · 2027Article
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- The bidirectional immunoregulatory effects of Traditional Chinese Medicine on the cGAS-STING signaling pathway and their translational prospects.Chinese medicine · 2026Review
- Review
- Self-assembled supramolecular nanoparticles ofActa pharmaceutica Sinica. B · 2026Article
- SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.Translational oncology · 2026Article
- Differential Expression of hsa-miR-34c-5p, hsa-miR-200b-3p, hsa-miR-320a-3p and Their Target Genes Determine Survival in Clear-Cell Renal Cell Carcinoma.Annals of surgical oncology · 2026Article
- Does acute inflammation triggered by infection promote cancer progression?PLoS biology · 2026Review
- The cGAS/STING pathway in cancer: translating innate DNA sensing into therapeutic potential.The Journal of clinical investigation · 2026Review
- Cell Selective STING-Activating Polysaccharide Immunomodulators for Cancer Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Dual-engineering metalloimmunotherapy mediatesBioactive materials · 2026Article
- Amine oxide lipid nanoparticles for delivery of cyclic dinucleotides.National science review · 2026Article
- DHRS9 generates crotonyl-CoA from butyryl-CoA to epigenetically regulate STING transcription and potentiate immune activation.Cell death and differentiation · 2026Article
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- The sleeping threat: targeting cancer dormancy to transform metastasis therapy.Nature reviews. Cancer · 2026Review
- ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Self-supplying hydrogen peroxide-driven gold nanoparticle aggregation via bio-orthogonal click reaction activates cGAS-STING-PERK pathway for multimodal tumor therapy.Journal of nanobiotechnology · 2026Article
- Microbiome-host interactions in different pathomic subtypes of early-stage lung adenocarcinoma.BMC pulmonary medicine · 2026Article
- L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis.Nature communications · 2026Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Jing HuCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francisco J Sánchez-RiveraCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8466-8563
Zhenghan WangCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gabriela N JohnsonCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu-Jui HoCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karuna GaneshMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4948-1082
Shigeaki UmedaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5693-1515
Siting GanCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adriana M MujalImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2559-8817
Rebecca B DelconteImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jessica P HamptonCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0084-5404
Huiyong ZhaoAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sanjay KottapalliComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisa de StanchinaAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christine A Iacobuzio-DonahueDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4672-3023
Dana Pe'erComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-9259-8817
Scott W LoweCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5284-9650
Joseph C SunImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8062-9033
Joan MassaguéCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. massaguj@mskcc.org.ORCID http://orcid.org/0000-0001-9324-8408
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MTumor-specific T cell state dynamics and heterogeneity in early tumorigenesisU54CA209975 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LESLIE, CHRISTINA S, RUDENSKY, ALEXANDER Y · 2016 to 2021
$11.8MThe TGF Beta Signaling Pathway in Development and CancerR35CA252978 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOAN MASSAGUE · 2020 to 2026
$7.3MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MInvestigating L1CAM-dependent stem cell regeneration in metastasisK08CA230213 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GANESH, KARUNA · 2018 to 2022
$1.3MNCI NIH HHS K08 CA230213NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA252978NCI NIH HHS T32 CA160001NCI NIH HHS U54 CA209975
Abstract
Metastasis frequently develops from disseminated cancer cells that remain dormant after the apparently successful treatment of a primary tumour. These cells fluctuate between an immune-evasive quiescent state and a proliferative state liable to immune-mediated elimination
Indexed as
Lung NeoplasmsNeoplasm MetastasisAdenocarcinoma of LungAnimalsCell CycleKiller Cells, NaturalMiceNeoplasm Recurrence, LocalSTING ProteinT-LymphocytesTransforming Growth Factor betaSting1 protein, mouseSTING ProteinTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.